EP0859633A2 - Procede de traitement des diabetes - Google Patents

Procede de traitement des diabetes

Info

Publication number
EP0859633A2
EP0859633A2 EP97938359A EP97938359A EP0859633A2 EP 0859633 A2 EP0859633 A2 EP 0859633A2 EP 97938359 A EP97938359 A EP 97938359A EP 97938359 A EP97938359 A EP 97938359A EP 0859633 A2 EP0859633 A2 EP 0859633A2
Authority
EP
European Patent Office
Prior art keywords
interferon
cells
insulin
cell
diabetes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP97938359A
Other languages
German (de)
English (en)
Inventor
Kurt B. Osther
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of EP0859633A2 publication Critical patent/EP0859633A2/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/249—Interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • the instant invention provides for a method for treating type I diabetes comprising intervention of interferon alpha activity.
  • the instant invention encompasses methods for treating early type I diabetes comprising administering an effective inhibitory amount of an antisense oligonucleotide directed to the mRNA encoding for interferon- ⁇ . Effective inhibition encompasses the complete or partial inhibition of transcription of the interferon alpha gene, or complete or partial inhibition of translation of the interferon alpha mRNA transcript.
  • spontaneously diabetic BB rats are another model system by which early intervention to prevent the effects of interferon, as a means of preventing the development of diabetes can be tested where there is a demonstrated genetic predisposition to develop diabetes.
  • the leftward boundary of the promoter is always upstream of the TATA box, a ubiquitous sequence of 7 or 8 bp that lies usually about 20 to 30 bp upstream from the starting point of transc ⁇ ption (Wagner R., Nature (1964) 204, 49).
  • Functional IFN mRNA cannot be extracted from unmduced cells. Transc ⁇ ption starts early after induction, the actual time being a function of the inducer-cell system studied. When human lymphoblastoid Namalwa cells are treated with the Sendai virus, IFN ⁇ and IFN ⁇ are produced (Havell E. et al., J. Gen. Virol. (1977) 38, 51).
  • the antisense molecule can be a native nucleic acid (DNA or RNA) or a modified nucleic acid.
  • modified antisense molecules one can use a phosphorothioate, a methylphosphonate, a PNA (Peptide Nucleic Acid), or any of the modifications commonly practiced ( see Crooke R.M. "In vitro toxicology and pharmacokinetics of antisense oligonucleotides, " 1991 , Anti-Cancer Drug Design, 6, 609-646.)
  • the main goal would be to utilize the transgenic techniques or the gene therapy for creating insulin producing cells to demonstrate the transfer the genes necessary to induce an insulin production in cells not used by the organism to produce insulin from said kind of cells.
  • the insulin gene may be dormant in the cell being used for the gene transfer and thereby the gene transfer would be to operably introduce the regulatory region of the insulin gene in order to create the insulin production. What is yet to be learned is whether the insulin gene composition necessary for the cell to excrete insulin otherwise would be present, and/or whether other gene products necessary for an actual production and excretion of insulin from the cell would be possible.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention se rapporte à des procédés et à des compositions qui permettent de traiter efficacement les diabètes de type I, lesdits procédés consistant à intervenir au niveau de l'activité de l'interféron alpha.
EP97938359A 1996-08-16 1997-08-15 Procede de traitement des diabetes Withdrawn EP0859633A2 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US69892696A 1996-08-16 1996-08-16
US76029996A 1996-12-04 1996-12-04
US760299 1996-12-04
PCT/US1997/014448 WO1998006431A2 (fr) 1996-08-16 1997-08-15 Procede de traitement des diabetes
US698926 2003-10-31

Publications (1)

Publication Number Publication Date
EP0859633A2 true EP0859633A2 (fr) 1998-08-26

Family

ID=27106305

Family Applications (1)

Application Number Title Priority Date Filing Date
EP97938359A Withdrawn EP0859633A2 (fr) 1996-08-16 1997-08-15 Procede de traitement des diabetes

Country Status (3)

Country Link
EP (1) EP0859633A2 (fr)
AU (1) AU4070897A (fr)
WO (1) WO1998006431A2 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007202840B2 (en) * 2001-01-09 2011-07-28 Baylor Research Institute Methods for treating autoimmune diseases in a subject and in vitro diagnostic assays
US7087726B2 (en) 2001-02-22 2006-08-08 Genentech, Inc. Anti-interferon-α antibodies
EP1851248B1 (fr) 2005-02-10 2016-08-10 Baylor Research Institute Anticorps monoclonaux anti-interferon alpha et procedes d'utilisation
ES2549903T3 (es) 2008-05-07 2015-11-03 Argos Therapeutics, Inc. Anticuerpos humanizados contra interferón alfa humano
US20140242038A1 (en) * 2011-10-11 2014-08-28 The Trustees Of Columbia University In The City Of New York Method for generating beta cells

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3005897A1 (de) * 1980-02-16 1981-09-03 Hoechst Ag, 6000 Frankfurt Genprodukt eines hoeheren organismus aus einem dieses gen enhtaltenden mikroorganismus
JPH06510061A (ja) * 1991-08-30 1994-11-10 ジェネンテク，インコーポレイテッド Ｉｄｄｍの治療法
IL106591A (en) * 1992-09-03 2008-03-20 Yeda Res & Dev Interferon alpha/beta binding protein, its preparation and pharmaceutical compositions containing it
WO1996034096A1 (fr) * 1995-04-28 1996-10-31 Abgenix, Inc. Anticorps humains derives de xeno-souris immunisees

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9806431A3 *

Also Published As

Publication number Publication date
WO1998006431A3 (fr) 1998-06-18
AU4070897A (en) 1998-03-06
WO1998006431A2 (fr) 1998-02-19

Similar Documents

Publication Publication Date Title
JP3867033B2 (ja) 疾患の治療的処置および予防のためにｂｃｌ−２を用いる方法
CN113528485B (zh) 治疗性核酸酶组合物和方法
US7438905B2 (en) Methods of suppressing, treating, or preventing graft rejection with an antibody or a portion thereof that binds to AILIM
US5759536A (en) Use of fas ligand to supress T-lymphocyte-mediated immune responses
CN1056427A (zh) 细胞增生疾病的基因疗法
KR20150003197A (ko) Toso 활성을 조절하기 위한 방법 및 조성물
Tamai et al. Cloning and expression of flatfish (Paralichthys olivaceus) interferon cDNA
WO2002101012A9 (fr) Regulation de l'expression transgenique suivant une transduction par aav
EP0601052A1 (fr) Procede therapeutique servant a traiter le diabete sucre insulinodependant.
Larin et al. Immunotherapy with autologous tumor cells engineered to secrete Tag7/PGRP, an innate immunity recognition molecule
WO1998006431A2 (fr) Procede de traitement des diabetes
Ghivizzani et al. Gene therapy approaches for treating rheumatoid arthritis
US7744894B2 (en) Method of treating multiple sclerosis and related t-cell initiated tissue destruction by administering HSA/CD24
KR20090090328A (ko) 조류 유래 에리트로포이어틴
US6677311B1 (en) Inducible HSV-TK in transformed cell populations
CN112840020A (zh) 溶瘤病毒及其应用
AU697095B2 (en) Expression of viral decoy proteins under the control of a locus control region and uses thereof
JP7374502B2 (ja) Ｏｃａ－ｂペプチドコンジュゲート及び処置方法
RU2846197C1 (ru) Универсальные донорские клетки и связанные с ними способы
CN101161676A (zh) 抑制hiv复制的突变型apobec3g分子及其应用
CN112538108B (zh) 高亲和pvr突变体
WO1997026325A1 (fr) Compositions et leurs utilisations pour le transfert de genes retro-regulateurs dans des cellules liees a des reponses inflammatoires
US8323963B2 (en) Construction and use of genes encoding pathogenic epitopes for treatment of autoimmune disease
ES2575629T3 (es) Polipéptido del Factor VIII
BG64829B1 (bg) Нови протеини, свързващи ifn рецептор 1, днк, която ги кодира, и методи за модулиране на клетъчен отговор спрямо интерферони

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

PUAK Availability of information related to the publication of the international search report

Free format text: ORIGINAL CODE: 0009015

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

R17D Deferred search report published (corrected)

Effective date: 19991007

R17D Deferred search report published (corrected)

Effective date: 19991008

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20000301